GLP-1 microdosing is the medical practice of administering very small doses of a drug, often to provide dose-specific benefits that might be different than the regular dose, while minimizing side effects
Potential risks of doubling up include: Severe, persistent nausea Projectile vomiting Intense abdominal cramping or pain Dehydration Extreme fatigue For a deeper look at digestive symptoms and management tips, read our semaglutide side effects guide
No, this new CMS program does not change our existing coverage
By activating both GIP and GLP-1, Mounjaro is particularly effective at reducing appetite and influencing the bodys natural fat-burning processes, leading to significant weight loss
However, in April 2025, the Trump administration officially rejected this proposal
People taking part in clinical trials for drugs based on semaglutide may also continue to take it